Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.

Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device ...

Given every human being is totally unique, it’s no surprise our bodies often behave in different ways. So, while you should ...

Both of Abbott's over-the-counter CGMS are based on its popular FreeStyle Libre sensor technology, as Dexcom's prescription-free Stelo follows the popular G6 and G7 CGM technology for people who ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Piper Sandler initiated coverage on Abbott Laboratories (NYSE:ABT) with an "overweight" rating and a price target of $131 per ...

led by FreeStyle Libre. The nutritional segment is benefiting from market share gains for its baby formula products. Abbott expects its total 2024 revenue to rise 9.5% to 10% on an organic basis.

DexCom's newest G7 CGM competes closely with Abbott's FreeStyle Libre 3, both products have very similar features and design innovations. DexCom's forward multiples suggest the company is trading ...

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who ...

Thursday is a big day for Texas A&M University-Fort Worth. But it’s just the first of many big days to come. Gov. Greg Abbott ...

Abbott Labs' key product line in its diabetes care segment is the FreeStyle Libre, a portfolio of continuous glucose monitoring (CGM) devices that allow diabetes patients to keep track of their ...